{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T03:01:40Z","timestamp":1787108500465,"version":"build-2736575974"},"reference-count":59,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,3,31]],"date-time":"2015-03-31T00:00:00Z","timestamp":1427760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","cell.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Microbiology"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.tim.2015.02.006","type":"journal-article","created":{"date-parts":[[2015,3,7]],"date-time":"2015-03-07T20:46:31Z","timestamp":1425761191000},"page":"429-436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Multipurpose prevention technologies: the future of HIV and STI protection"],"prefix":"10.1016","volume":"23","author":[{"given":"Jos\u00e9 A.","family":"Fern\u00e1ndez-Romero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy C.","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorothy","family":"Patton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zydowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Petro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjulaa","family":"Narasimhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 4","key":"10.1016\/j.tim.2015.02.006_bib0300","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1097\/01.aids.0000390704.35642.47","article-title":"Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning?","volume":"24","author":"Hayes","year":"2010","journal-title":"Aids"},{"key":"10.1016\/j.tim.2015.02.006_bib0305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0168-1702(02)00189-2","article-title":"Cervical and anal HPV infections in HIV positive women and men","volume":"89","author":"de Sanjose","year":"2002","journal-title":"Virus Res."},{"key":"10.1016\/j.tim.2015.02.006_bib0310","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1186\/1471-2334-13-502","article-title":"Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies","volume":"13","author":"Tan","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0315","doi-asserted-by":"crossref","first-page":"F85","DOI":"10.1097\/00002030-199712000-00001","article-title":"The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Cote d\u2019Ivoire","volume":"11","author":"Ghys","year":"1997","journal-title":"Aids"},{"key":"10.1016\/j.tim.2015.02.006_bib0320","article-title":"Preclinical assessments of vaginal microbicide candidate safety and efficacy","author":"Fernandez-Romero","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.tim.2015.02.006_bib0325","doi-asserted-by":"crossref","first-page":"805","DOI":"10.2471\/BLT.07.046128","article-title":"An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection","volume":"86","author":"Looker","year":"2008","journal-title":"Bull. World Health Organ."},{"key":"10.1016\/j.tim.2015.02.006_bib0330","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa035144","article-title":"Once-daily valacyclovir to reduce the risk of transmission of genital herpes","volume":"350","author":"Corey","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0335","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/01.aids.0000198081.09337.a7","article-title":"Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta-analysis of longitudinal studies","volume":"20","author":"Freeman","year":"2006","journal-title":"Aids"},{"key":"10.1016\/j.tim.2015.02.006_bib0340","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/505496","article-title":"Management of herpes simplex virus type 2 infection in HIV type 1-infected persons","volume":"43","author":"Strick","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0345","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0350","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1126\/science.1193748","article-title":"Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women","volume":"329","author":"Abdool Karim","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.tim.2015.02.006_bib0355","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7326\/M13-2471","article-title":"Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial","volume":"161","author":"Celum","year":"2014","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0360","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1093\/jac\/dks097","article-title":"Intravaginal ring delivery of tenofovir disoproxil fumarate for prevention of HIV and herpes simplex virus infection","volume":"67","author":"Mesquita","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tim.2015.02.006_bib0365","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/AAC.01818-13","article-title":"Vaginally delivered tenofovir disoproxil fumarate provides greater protection than tenofovir against genital herpes in a murine model of efficacy and safety","volume":"58","author":"Nixon","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2015.02.006_bib0370","doi-asserted-by":"crossref","first-page":"9345","DOI":"10.1074\/jbc.M411122200","article-title":"Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp","volume":"280","author":"Mori","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tim.2015.02.006_bib0375","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1073\/pnas.0901506106","article-title":"Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component","volume":"106","author":"O\u2019Keefe","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.tim.2015.02.006_bib0380","doi-asserted-by":"crossref","first-page":"6257","DOI":"10.1128\/JVI.00012-13","article-title":"Griffithsin protects mice from genital herpes by preventing cell-to-cell spread","volume":"87","author":"Nixon","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2015.02.006_bib0385","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1086\/522606","article-title":"Seminal plasma reduces the effectiveness of topical polyanionic microbicides","volume":"196","author":"Patel","year":"2007","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0390","doi-asserted-by":"crossref","first-page":"e27675","DOI":"10.1371\/journal.pone.0027675","article-title":"Bridging the gap between preclinical and clinical microbicide trials: blind evaluation of candidate gels in murine models of efficacy and safety","volume":"6","author":"Segarra","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tim.2015.02.006_bib0395","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1128\/AAC.05461-11","article-title":"Zinc acetate\/carrageenan gels exhibit potent activity in vivo against high-dose herpes simplex virus 2 vaginal and rectal challenge","volume":"56","author":"Fernandez-Romero","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2015.02.006_bib0400","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1128\/AAC.00796-13","article-title":"A modified zinc acetate gel, a potential nonantiretroviral microbicide, is safe and effective against simian-human immunodeficiency virus and herpes simplex virus 2 infection in vivo","volume":"57","author":"Kenney","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tim.2015.02.006_bib0405","doi-asserted-by":"crossref","first-page":"e94547","DOI":"10.1371\/journal.pone.0094547","article-title":"A potent combination microbicide that targets SHIV-RT, HSV-2 and HPV","volume":"9","author":"Kizima","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.tim.2015.02.006_bib0410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.antiviral.2014.05.018","article-title":"In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition","volume":"108","author":"Rodriguez","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.tim.2015.02.006_bib0415","doi-asserted-by":"crossref","first-page":"11236","DOI":"10.1128\/JVI.76.22.11236-11244.2002","article-title":"Mandelic acid condensation polymer: novel candidate microbicide for prevention of human immunodeficiency virus and herpes simplex virus entry","volume":"76","author":"Herold","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2015.02.006_bib0420","doi-asserted-by":"crossref","first-page":"6576","DOI":"10.1128\/JVI.00335-08","article-title":"Candidate microbicide PPCM blocks human immunodeficiency virus type 1 infection in cell and tissue cultures and prevents genital herpes in a murine model","volume":"82","author":"Mesquita","year":"2008","journal-title":"J. Virol."},{"issue":"Suppl. 5","key":"10.1016\/j.tim.2015.02.006_bib0425","doi-asserted-by":"crossref","first-page":"F55","DOI":"10.1016\/j.vaccine.2012.06.083","article-title":"The biology and life-cycle of human papillomaviruses","volume":"30","author":"Doorbar","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2015.02.006_bib0430","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nm1598","article-title":"Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan","volume":"13","author":"Roberts","year":"2007","journal-title":"Nat. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0435","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/jnci\/djr061","article-title":"Effect of Pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model","volume":"103","author":"Roberts","year":"2011","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.tim.2015.02.006_bib0440","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1128\/JVI.02190-08","article-title":"Role of heparan sulfate in attachment to and infection of the murine female genital tract by human papillomavirus","volume":"83","author":"Johnson","year":"2009","journal-title":"J. Virol."},{"key":"10.1016\/j.tim.2015.02.006_bib0445","doi-asserted-by":"crossref","first-page":"20458","DOI":"10.1073\/pnas.0908502106","article-title":"The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding","volume":"106","author":"Kines","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"Suppl. 5","key":"10.1016\/j.tim.2015.02.006_bib0450","doi-asserted-by":"crossref","first-page":"F123","DOI":"10.1016\/j.vaccine.2012.04.108","article-title":"A review of clinical trials of human papillomavirus prophylactic vaccines","volume":"30","author":"Schiller","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.tim.2015.02.006_bib0455","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.chom.2010.08.003","article-title":"In vivo mechanisms of vaccine-induced protection against HPV infection","volume":"8","author":"Day","year":"2010","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tim.2015.02.006_bib0460","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1016\/S1470-2045(14)71191-X","article-title":"FDA approves new upgraded Gardasil 9","volume":"16","author":"Kirby","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tim.2015.02.006_bib0465","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1940-6207.CAPR-11-0542","article-title":"Reducing HPV-associated cancer globally","volume":"5","author":"Lowy","year":"2012","journal-title":"Cancer Prev. Res."},{"key":"10.1016\/j.tim.2015.02.006_bib0470","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/QAI.0b013e3181b327e7","article-title":"Association of oncogenic and nononcogenic human papillomavirus with HIV incidence","volume":"53","author":"Auvert","year":"2010","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tim.2015.02.006_bib0475","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/sextrans-2011-050346","article-title":"Association of genital human papillomavirus infection with HIV acquisition: a systematic review and meta-analysis","volume":"89","author":"Lissouba","year":"2013","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.tim.2015.02.006_bib0480","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1371\/journal.ppat.0020069","article-title":"Carrageenan is a potent inhibitor of papillomavirus infection","volume":"2","author":"Buck","year":"2006","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tim.2015.02.006_bib0485","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3851\/IMP1890","article-title":"The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection","volume":"16","author":"Marais","year":"2011","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.tim.2015.02.006_bib0590","series-title":"Global Incidence and Prevalence of Selected Curable Sexually Transmitted Infections \u2013 2008","year":"2012"},{"key":"10.1016\/j.tim.2015.02.006_bib0490","first-page":"238","article-title":"The activity of 1-(2-hydroxyethyl)-2-methyl-5-nitroimidazole (R.P. 8823) against experimental Trichomonas vaginalis infections","volume":"96","author":"Cosar","year":"1959","journal-title":"Ann. Inst. Pasteur."},{"key":"10.1016\/j.tim.2015.02.006_bib0495","doi-asserted-by":"crossref","first-page":"939","DOI":"10.3201\/eid1806.111590","article-title":"Trichomonas vaginalis antimicrobial drug resistance in 6 US cities, STD Surveillance Network, 2009\u20132010","volume":"18","author":"Kirkcaldy","year":"2012","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0500","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1136\/sextrans-2014-051537","article-title":"HPTN 035 phase II\/IIb randomised safety and effectiveness study of the vaginal microbicides BufferGel and 0.5% PRO 2000 for the prevention of sexually transmitted infections in women","volume":"90","author":"Guffey","year":"2014","journal-title":"Sex. Transm. Infect."},{"key":"10.1016\/j.tim.2015.02.006_bib0505","series-title":"Trichomonads Parasitic in Humans","first-page":"112","article-title":"Employment of experimental animals in studies of Trichomonas vaginalis infections","author":"Kulda","year":"1990"},{"key":"10.1016\/j.tim.2015.02.006_bib0510","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1128\/IAI.64.9.3571-3575.1996","article-title":"Inducible immunity to Trichomonas vaginalis in a mouse model of vaginal infection","volume":"64","author":"Abraham","year":"1996","journal-title":"Infect. Immun."},{"key":"10.1016\/j.tim.2015.02.006_bib0515","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4269\/ajtmh.2000.63.284","article-title":"Use of intravaginal microbicides to prevent acquisition of Trichomonas vaginalis infection in Lactobacillus-pretreated, estrogenized young mice","volume":"63","author":"Lushbaugh","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.tim.2015.02.006_bib0520","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/01.olq.0000218871.89901.61","article-title":"Development of a nonhuman primate model for Trichomonas vaginalis infection","volume":"33","author":"Patton","year":"2006","journal-title":"Sex. Transm. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0525","first-page":"790154","article-title":"Developing multipurpose reproductive health technologies: an integrated strategy","volume":"2013","author":"Harrison","year":"2013","journal-title":"AIDS Res. Treat."},{"issue":"Suppl. 5","key":"10.1016\/j.tim.2015.02.006_bib0530","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/1471-0528.12844","article-title":"Aligning product development and user perspectives: social-behavioural dimensions of multipurpose prevention technologies","volume":"121","author":"Brady","year":"2014","journal-title":"Bjog"},{"key":"10.1016\/j.tim.2015.02.006_bib0535","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1097\/QAI.0000000000000134","article-title":"Significant decrease of ethinylestradiol with nevirapine, and of etonogestrel with efavirenz in HIV-positive women","volume":"66","author":"Landolt","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tim.2015.02.006_bib0540","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/QAI.0000000000000189","article-title":"Effect of antiretroviral therapy including lopinavir\/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women","volume":"66","author":"Vieira","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tim.2015.02.006_bib0545","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/QAD.0000000000000177","article-title":"Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leading to unintended pregnancies","volume":"28","author":"Perry","year":"2014","journal-title":"Aids"},{"key":"10.1016\/j.tim.2015.02.006_bib0550","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1473-3099(11)70247-X","article-title":"Use of hormonal contraceptives and risk of HIV-1 transmission: a prospective cohort study","volume":"12","author":"Heffron","year":"2012","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0555","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0560","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tim.2015.02.006_bib0565","doi-asserted-by":"crossref","first-page":"19146","DOI":"10.7448\/IAS.17.3.19146","article-title":"Perspectives on use of oral and vaginal antiretrovirals for HIV prevention: the VOICE-C qualitative study in Johannesburg, South Africa","volume":"17","author":"van der Straten","year":"2014","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.tim.2015.02.006_bib0570","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1473-3099(14)70937-5","article-title":"Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial","volume":"14","author":"Baeten","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.tim.2015.02.006_bib0575","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.tim.2015.02.006_bib0580","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/1471-0528.12911","article-title":"Ensuring successful development and introduction of multipurpose prevention technologies through an innovative partnership approach","volume":"121","author":"Young Holt","year":"2014","journal-title":"BJOG"},{"issue":"Suppl. 5","key":"10.1016\/j.tim.2015.02.006_bib0585","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/1471-0528.13024","article-title":"Challenges and opportunities in funding the development and introduction of multipurpose prevention technologies","volume":"121","author":"Manning","year":"2014","journal-title":"BJOG"}],"container-title":["Trends in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X15000451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966842X15000451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T16:15:03Z","timestamp":1598804103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966842X15000451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":59,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0966842X15000451"],"URL":"https:\/\/doi.org\/10.1016\/j.tim.2015.02.006","relation":{},"ISSN":["0966-842X"],"issn-type":[{"value":"0966-842X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multipurpose prevention technologies: the future of HIV and STI protection","name":"articletitle","label":"Article Title"},{"value":"Trends in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tim.2015.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}